What is Denosumab or Prolia®?
Denosumab is a monoclonal antibody for the treatment of postmenopausal osteoporosis and is given by injection every six months. Prolia works by decreasing the activity of osteoclasts at the molecular level, helping the bone building cells increase bone mass. Prolia is recommended for women with osteoporosis and high fracture risk, which includes patients who have had an osteoporotic fracture, have several risk factors, or have not responded to other treatments.
What are the side effects of denosumab?
Side effects may include back and muscle pain, pain in the extremities, elevation of lipids in the blood, and bladder infection.